Neurodawn Pharmaceutical Co., Ltd.
Clinical trials sponsored by Neurodawn Pharmaceutical Co., Ltd., explained in plain language.
-
Can a dissolving tablet improve recovery after a common stroke?
Disease control Not yet recruitingThis trial tests whether Y-6 sublingual tablets can help people recover from a specific type of stroke called acute perforator artery infarction. About 944 adults who have had a stroke within the past 72 hours will receive either Y-6 or a placebo twice daily for 90 days. Research…
Phase: PHASE2, PHASE3 • Sponsor: Neurodawn Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Bone marrow injection shows promise for severe stroke
Disease control Not yet recruitingThis early-phase study tests a new drug called RK-4 for people with a severe type of stroke (large hemispheric infarction) who cannot have standard clot-removal treatment. The drug is injected directly into the skull bone marrow once daily for three days. The main goals are to ch…
Phase: PHASE1, PHASE2 • Sponsor: Neurodawn Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug Y-4 tested against pregabalin and riluzole in healthy volunteers
Knowledge-focused Not yet recruitingThis early-stage study tests a new drug called Y-4 in 11 healthy adults to see how it moves through the body compared to pregabalin and riluzole. Participants take each drug once, and researchers measure drug levels and check for side effects. The goal is to gather information, n…
Phase: PHASE1 • Sponsor: Neurodawn Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC